IDEXX LABORATORIES INC /DE Earnings Summary — Q1 2026
IDEXX Starts 2026 with Strong Earnings Growth and Continued Margin Expansion
Key Takeaways
- Revenue grew 14.3% YoY to $1.14 billion, demonstrating high-quality organic growth consistent with the prior quarter.
- Net income increased by 14.7% YoY, matching revenue growth and indicating stable profitability profiles.
- Operating income reached $362.6 million, a significant recovery from the year-end Q4 lows.
- Selling, General & Administrative expenses rose to $294.4 million, reflecting continued investment in the global sales force.
- Research & Development spending remains steady at $65.8 million, supporting the innovation pipeline.
- The 'razor-razorblade' model continues to drive robust recurring revenue from companion animal diagnostic consumables.
- Shares outstanding have decreased to 80 million, reflecting the company's historical commitment to buyback-driven shareholder returns.
Management Guidance
Management remains focused on the Companion Animal Group (CAG) growth and expanding recurring diagnostic revenue through clinical decision support software.
Sentiment Shift
Stable
Performance remains consistently high with double-digit growth echoing the multi-year compounding trend reported in recent annual periods.
Outlook
The company is positioned for continued expansion driven by secular pet humanization trends and a matured, self-sustaining capital structure.
From the Annual Report (Key Quotes)
“IDEXX Laboratories presents a masterclass in compounding within the resilient veterinary diagnostics and software ecosystem.”
“The business model is fortified by high-margin recurring revenue from diagnostic consumables and laboratory services.”
“Management has successfully navigated global supply chain challenges while maintaining double-digit revenue growth.”
Official Quarterly Documents
This summary is AI-generated from IDEXX LABORATORIES INC /DE's latest quarterly filing and earnings call. For informational purposes only — not investment advice.